Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Colorectal Neoplasms

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 85 articles:
HTML format

Single Articles

    November 2022
  1. KEANE JM, Walsh CJ, Cronin P, Baker K, et al
    Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints.
    Br J Cancer. 2022 Nov 23. doi: 10.1038/s41416-022-02062.
    PubMed     Abstract available

  2. HONG XL, Yu TC, Huang XW, Wang JL, et al
    Metformin abrogates Fusobacterium nucleatum-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic hedgehog signaling-regulated stemness.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02044.
    PubMed     Abstract available

  3. PROPPER DJ, Gao F, Saunders MP, Sarker D, et al
    PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
    Br J Cancer. 2022 Nov 9. pii: 10.1038/s41416-022-02015.
    PubMed     Abstract available

  4. FAULKNER LG, Howells LM, Pepper C, Shaw JA, et al
    The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02017.
    PubMed     Abstract available

  5. LI SJ, Seedher T, Sharples LD, Benton SC, et al
    Impact of changes to the interscreening interval and faecal immunochemical test threshold in the national bowel cancer screening programme in England: results from the FIT pilot study.
    Br J Cancer. 2022;127:1525-1533.
    PubMed     Abstract available

  6. CHEN KH, Hsu CL, Su YL, Yuan CT, et al
    Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02010.
    PubMed     Abstract available

  7. OKADA Y, Peng F, Perea J, Corchete L, et al
    Genome-wide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02033.
    PubMed     Abstract available

    October 2022
  8. MELTZER S, Negard A, Bakke KM, Hamre HM, et al
    Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer.
    Br J Cancer. 2022 Oct 13. pii: 10.1038/s41416-022-02004.
    PubMed     Abstract available

  9. LIU Y, Zhang L, Chen X, Chen D, et al
    The novel FGFR inhibitor F1-7 induces DNA damage and cell death in colon cells.
    Br J Cancer. 2022;127:1014-1025.
    PubMed     Abstract available

  10. JAN YH, Tan KT, Chen SJ, Yip TTC, et al
    Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
    Br J Cancer. 2022;127:1304-1311.
    PubMed     Abstract available

    September 2022
  11. ZHANG Y, Song M, Chan AT, Meyerhardt JA, et al
    Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01975.
    PubMed     Abstract available

  12. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
    Br J Cancer. 2022 Sep 17. pii: 10.1038/s41416-022-01940.
    PubMed     Abstract available

  13. YKEMA BLM, Breekveldt ECH, Carvalho B, van Wezel T, et al
    Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors.
    Br J Cancer. 2022 Sep 10. pii: 10.1038/s41416-022-01972.
    PubMed     Abstract available

  14. EMONS G, Auslander N, Jo P, Kitz J, et al
    Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy.
    Br J Cancer. 2022;127:766-775.
    PubMed     Abstract available

    August 2022
  15. HSIEH CC, Hsu SH, Lin CY, Liaw HJ, et al
    CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01946.
    PubMed     Abstract available

    July 2022
  16. CHAKROBORTY D, Goswami S, Fan H, Frankel WL, et al
    Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer.
    Br J Cancer. 2022 Jul 28. pii: 10.1038/s41416-022-01916.
    PubMed     Abstract available

  17. FOERSCH S, Lang-Schwarz C, Eckstein M, Geppert C, et al
    pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassification.
    Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01889.
    PubMed     Abstract available

  18. RAMSAY RG, Flood M
    New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC.
    Br J Cancer. 2022 Jul 13. pii: 10.1038/s41416-022-01905.
    PubMed     Abstract available

  19. PANG X, Xie P, Yu L, Chen H, et al
    A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer.
    Br J Cancer. 2022;127:268-277.
    PubMed     Abstract available

  20. SONG M, Li S, Wang H, Hu K, et al
    MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer.
    Br J Cancer. 2022;127:249-257.
    PubMed     Abstract available

    June 2022
  21. ZAMAN FY, Orchard SG, Haydon A, Zalcberg JR, et al
    Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.
    Br J Cancer. 2022 Jun 28. pii: 10.1038/s41416-022-01882.
    PubMed     Abstract available

  22. ARORA SP, Tenner L, Sarantopoulos J, Morris J, et al
    Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
    Br J Cancer. 2022 Jun 23. pii: 10.1038/s41416-022-01892.
    PubMed     Abstract available

  23. HASHIMOTO T, Takayanagi D, Yonemaru J, Naka T, et al
    Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01880.
    PubMed     Abstract available

  24. MORETTO R, Elliott A, Rossini D, Intini R, et al
    Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
    Br J Cancer. 2022 Jun 3. pii: 10.1038/s41416-022-01852.
    PubMed     Abstract available

  25. DI MARTINO E, Smith L, Bradley SH, Hemphill S, et al
    Incidence trends for twelve cancers in younger adults-a rapid review.
    Br J Cancer. 2022;126:1374-1386.
    PubMed     Abstract available

  26. KLEIF J, Jorgensen LN, Hendel JW, Madsen MR, et al
    Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening.
    Br J Cancer. 2022;126:1387-1393.
    PubMed     Abstract available

  27. GINER-CALABUIG M, De Leon S, Wang J, Fehlmann TD, et al
    Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential.
    Br J Cancer. 2022;126:1595-1603.
    PubMed     Abstract available

  28. LI H, van der Merwe PA, Sivakumar S
    Biomarkers of response to PD-1 pathway blockade.
    Br J Cancer. 2022;126:1663-1675.
    PubMed     Abstract available

  29. LI Z, Wang K, Shivappa N, Hebert JR, et al
    Inflammatory potential of diet and colorectal carcinogenesis: a prospective longitudinal cohort.
    Br J Cancer. 2022;126:1735-1743.
    PubMed     Abstract available

  30. LATACZ E, Hoppener D, Bohlok A, Leduc S, et al
    Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.
    Br J Cancer. 2022 Jun 1. pii: 10.1038/s41416-022-01859.
    PubMed     Abstract available

    May 2022
  31. JUNG SH, Kim D, Park JW
    Reply to comment(s) on "Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index".
    Br J Cancer. 2022 May 31. pii: 10.1038/s41416-022-01862.

  32. XIE H, Ge Y, Shi H
    Comment on "Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index".
    Br J Cancer. 2022 May 31. pii: 10.1038/s41416-022-01861.

  33. FISCHER LE, Stintzing S, von Weikersthal LF, Modest DP, et al
    Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Br J Cancer. 2022 May 30. pii: 10.1038/s41416-022-01854.
    PubMed     Abstract available

  34. KIM S, Lim Y, Kang JK, Kim HP, et al
    Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.
    Br J Cancer. 2022 May 28. pii: 10.1038/s41416-022-01837.
    PubMed     Abstract available

  35. UUTELA A, Osterlund E, Halonen P, Kallio R, et al
    Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
    Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01858.
    PubMed     Abstract available

  36. YU L, Guo Q, Luo Z, Wang Y, et al
    TXN inhibitor impedes radioresistance of colorectal cancer cells with decreased ALDH1L2 expression via TXN/NF-kappaB signaling pathway.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01835.
    PubMed     Abstract available

  37. SCHMID F, Dahlmann M, Rohrich H, Kobelt D, et al
    Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01833.
    PubMed     Abstract available

  38. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available

    Editorial on "A systematic review of microbial markers for risk prediction of colorectal neoplasia" by Yu and coauthors.
    Br J Cancer. 2022;126:1239-1240.
    PubMed     Abstract available

  40. YU L, Zhao G, Wang L, Zhou X, et al
    A systematic review of microbial markers for risk prediction of colorectal neoplasia.
    Br J Cancer. 2022;126:1318-1328.
    PubMed     Abstract available

  41. MESSAOUDI N, Henault D, Stephen D, Cousineau I, et al
    Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns.
    Br J Cancer. 2022;126:1329-1338.
    PubMed     Abstract available

    April 2022
  42. ELOMAA H, Ahtiainen M, Vayrynen SA, Ogino S, et al
    Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01822.
    PubMed     Abstract available

  43. BUCCHI L, Mancini S, Baldacchini F, Ravaioli A, et al
    How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study.
    Br J Cancer. 2022 Apr 20. pii: 10.1038/s41416-022-01813.
    PubMed     Abstract available

  44. VAN CUTSEM E, Danielewicz I, Saunders MP, Pfeiffer P, et al
    First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01737.
    PubMed     Abstract available

  45. CALLESEN LB, Hamfjord J, Boysen AK, Pallisgaard N, et al
    Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01816.
    PubMed     Abstract available

  46. BOGIE RMM, le Clercq CMC, Voorham QJM, Cordes M, et al
    Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study.
    Br J Cancer. 2022;126:865-873.
    PubMed     Abstract available

    March 2022
  47. SOLIS-FERNANDEZ G, Montero-Calle A, Sanchez-Martinez M, Pelaez-Garcia A, et al
    Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis.
    Br J Cancer. 2022 Mar 28. pii: 10.1038/s41416-022-01762.
    PubMed     Abstract available

  48. STRATING E, Wassenaar E, Verhagen M, Rauwerdink P, et al
    Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by (68)Ga-FAPI-PET imaging.
    Br J Cancer. 2022 Mar 16. pii: 10.1038/s41416-022-01748.
    PubMed     Abstract available

  49. MAURI G, Vitiello PP, Sogari A, Crisafulli G, et al
    Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
    Br J Cancer. 2022 Mar 9. pii: 10.1038/s41416-022-01769.
    PubMed     Abstract available

  50. JUNG SH, Hao J, Shivakumar M, Nam Y, et al
    Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index.
    Br J Cancer. 2022 Mar 5. pii: 10.1038/s41416-022-01767.
    PubMed     Abstract available

  51. LASZLO HE, Seward E, Ayling RM, Lake J, et al
    Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.
    Br J Cancer. 2022;126:736-743.
    PubMed     Abstract available

  52. LARSEN SG, Goscinski MA, Dueland S, Steigen SE, et al
    Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
    Br J Cancer. 2022;126:726-735.
    PubMed     Abstract available

    February 2022
  53. LAOUKILI J, Constantinides A, Wassenaar ECE, Elias SG, et al
    Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-022-01742.
    PubMed     Abstract available

  54. PATEL M, Pennel KAF, Quinn JA, Hood H, et al
    Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer.
    Br J Cancer. 2022 Feb 16. pii: 10.1038/s41416-022-01729.
    PubMed     Abstract available

  55. HAREWOOD R, Wooldrage K, Robbins EC, Kinross J, et al
    Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01719.
    PubMed     Abstract available

    January 2022
  56. THOMSEN MK, Pedersen L, Erichsen R, Lash TL, et al
    Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
    Br J Cancer. 2022 Jan 20. pii: 10.1038/s41416-022-01709.
    PubMed     Abstract available

  57. LAL N, Chan DKH, Ng ME, Vermeulen L, et al
    Primary tumour immune response and lymph node yields in colon cancer.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01700.
    PubMed     Abstract available

  58. TRAN TN, Peeters M, Hoeck S, Van Hal G, et al
    Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01694.
    PubMed     Abstract available

  59. YCHOU M, Rivoire M, Thezenas S, Guimbaud R, et al
    Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
    Br J Cancer. 2022 Jan 6. pii: 10.1038/s41416-021-01644.
    PubMed     Abstract available

    December 2021
  60. GUO S, Li J, Huang Z, Yue T, et al
    The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation.
    Br J Cancer. 2021 Dec 24. pii: 10.1038/s41416-021-01681.
    PubMed     Abstract available

  61. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
    CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
    PubMed     Abstract available

  62. ELEZ E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, et al
    Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
    Br J Cancer. 2021 Dec 22. pii: 10.1038/s41416-021-01638.
    PubMed     Abstract available

  63. MCDOWELL R, Perrott S, Murchie P, Cardwell C, et al
    Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database.
    Br J Cancer. 2021 Dec 17. pii: 10.1038/s41416-021-01665.
    PubMed     Abstract available

  64. ZHANG X, Li X, He Y, Law PJ, et al
    Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
    PubMed     Abstract available

  65. MATSUMOTO T, Okayama H, Nakajima S, Saito K, et al
    SH2D4A downregulation due to loss of chromosome 8p is associated with poor prognosis and low T cell infiltration in colorectal cancer.
    Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01660.
    PubMed     Abstract available

    November 2021
  66. MANCA P, Corallo S, Lonardi S, Fuca G, et al
    Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01591.
    PubMed     Abstract available

  67. DASH P, Ghatak S, Topi G, Satapathy SR, et al
    High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model.
    Br J Cancer. 2021 Nov 8. pii: 10.1038/s41416-021-01595.
    PubMed     Abstract available

  68. MAJANO SB, Lyratzopoulos G, Rachet B, de Wit NJ, et al
    Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01603.
    PubMed     Abstract available

    October 2021
  69. TAKEDA T, Yokoyama Y, Takahashi H, Okuzaki D, et al
    A stem cell marker KLF5 regulates CCAT1 via three-dimensional genome structure in colorectal cancer cells.
    Br J Cancer. 2021 Oct 27. pii: 10.1038/s41416-021-01579.
    PubMed     Abstract available

  70. OUAHOUD S, Jacobs RJ, Kodach LL, Voorneveld PW, et al
    Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01604.
    PubMed     Abstract available

  71. OHSHIMA K, Oi R, Okuzaki D, Motooka D, et al
    Mitochondrial matrix protein C14orf159 attenuates colorectal cancer metastasis by suppressing Wnt/beta-catenin signalling.
    Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01582.
    PubMed     Abstract available

  72. ARAI H, Xiao Y, Millstein J, Wang J, et al
    Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01592.
    PubMed     Abstract available

  73. AASEBO K, Bruun J, Bergsland CH, Nunes L, et al
    Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01586.
    PubMed     Abstract available

  74. KONUKIEWITZ B, Schmitt M, Silva M, Pohl J, et al
    Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
    Br J Cancer. 2021 Oct 6. pii: 10.1038/s41416-021-01553.
    PubMed     Abstract available

    September 2021
  75. ZHANG J, Nyvang D, Ibsen DB, Olsen A, et al
    Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study.
    Br J Cancer. 2021 Sep 30. pii: 10.1038/s41416-021-01556.
    PubMed     Abstract available

  76. CHEN D, Bao X, Zhang R, Ding Y, et al
    Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
    Br J Cancer. 2021;125:994-1002.
    PubMed     Abstract available

  77. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available

    July 2021
  78. MELTZER S, Torgunrud A, Abrahamsson H, Solbakken AM, et al
    The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.
    Br J Cancer. 2021;125:240-246.
    PubMed     Abstract available

    June 2021
  79. DIXON SW, Collard TJ, Mortensson EMH, Legge DN, et al
    5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
    Br J Cancer. 2021;124:1959-1969.
    PubMed     Abstract available

    May 2021
  80. KANE AM, Liu C, Fennell LJ, McKeone DM, et al
    Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
    Br J Cancer. 2021;124:1820-1827.
    PubMed     Abstract available

  81. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available

    April 2021
  82. THOMSON A, Bento DFC, Scurr MJ, Smart K, et al
    Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells.
    Br J Cancer. 2021;124:1552-1555.
    PubMed     Abstract available

    March 2021
  83. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available

  84. NIMPTSCH K, Lee DH, Zhang X, Song M, et al
    Dairy intake during adolescence and risk of colorectal adenoma later in life.
    Br J Cancer. 2021;124:1160-1168.
    PubMed     Abstract available

    February 2021
  85. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.